NCLT Chandigarh allows Fortis to withdraw SRL demerger scheme

The National Company Law Tribunal bench in Chandigarh has allowed Fortis Healthcare to withdraw its scheme to demerge SRL diagnostics from the group and merge it with its step down subsidiary, the company told stock exchanges on Friday.

Fortis wanted to withdraw the composite scheme of arrangement and amalgamation between the group, Fortis Malar Hospitals and SRL due to reasons beyond the its control and its recently launched fresh bidding process for a deal.

The process was to take 6-8 months but has taken over 19 months and is still not complete, the company told BSE on Thursday.

  • Related Posts

    Lilly launches Mounjaro KwikPen in India

    Mumbai, August 14, 2025 — Eli Lilly and Company (India) has rolled out the Mounjaro (tirzepatide) KwikPen across the country, expanding treatment choices for people with type-2 diabetes and those…

    Fortis Q1 Profit Jumps 57%; Expansion Drives Growth

      Gurugram, August 7 – http://Fortis HealthcareFortis Healthcare has reported a 57% year-on-year increase in its net profit for the first quarter of FY2025. The hospital chain posted ₹260 crore…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    CSIR-CCMB Hyderabad developed DNA barcoding technology

    CSIR-CCMB Hyderabad developed DNA barcoding technology

    Uttar Pradesh: Fake Deworming Drugs Uncovered in Animal Husbandry Department

    Uttar Pradesh: Fake Deworming Drugs Uncovered in Animal Husbandry Department

    Police bust illegal medicine supply racket

    Police bust illegal medicine supply racket

    2 medical store owners held in drug supply racket in Delhi

    2 medical store owners held in drug supply racket in Delhi

    Maharashtra FDA appoints 34 lab personnel for its Mumbai based drug testing lab

    Maharashtra FDA appoints 34 lab personnel for its Mumbai based drug testing lab

    Ayush export declines by 7.4% in first nine months of FY 26

    Ayush export declines by 7.4% in first nine months of FY 26